Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.68 |
| ▸ | GABRD | O14764 | 1/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.68 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.68 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.68 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.68 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.68 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.68 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.68 |
| ▸ | GABRE | P78334 | 1/20 | 0.68 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.68 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.68 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.68 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.68 |
| ▸ | CCKBR | P32239 | 13/20 | 0.56 |
| ▸ | CCKAR | P32238 | 4/20 | 0.52 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.49 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487036 | 0.99 | GABRP (0.70) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL6797578 | 0.87 | GABRP (0.73) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL6797581 | 0.87 | GABRP (0.73) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4115829 | 0.86 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287888 | 0.86 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3289463 | 0.86 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL6797572 | 0.84 | GABRP (0.71) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3287928 | 0.84 | GABRP (0.74) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2923672 | 0.82 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1835654 | 0.82 | GABRA1 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-25 | — | — | US | disclosed |
| US-7655647-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-07-02 | — | — | US | disclosed |
| US-7498324-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7276495-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-07-26 | — | — | US | disclosed |
| US-20060211679-A1 | Substituted lactams as inhibitors of Abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
| US-20050234039-A1 | Prevent forming deposits of amyloid protein on nervous systems; Alzheimer's disease; Down syndrome | HAN QI | 2005-10-20 | — | — | US | disclosed |
| US-6900199-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040138201-A1 | Substituted lactams as inhibitors of Abeta protein production | HAN QI (US) | 2004-07-15 | — | — | US | disclosed |
| US-6632812-B2 | Alzheimer's disease; Down syndrom | DUPONT PHARMACEUTICALS COMPANY | 2003-10-14 | — | — | US | disclosed |
| EP-1289966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2001077086-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20020025955-A1 | Substituted lactams as inhibitors of A beta protein production | BACE1, APP, APH1A | GABRP 293/4885GABRD 878/4885GABRA1 1209/4885 |
| US-20100009966-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20100048541-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20090170831-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | GABRP 180/4885GABRD 505/4885GABRA1 913/4885 |
| US-20040138201-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | GABRP 274/4885GABRD 705/4885GABRA1 1224/4885 |
| US-20060211679-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20070173491-A1 | Substituted lactams as inhibitors of Abeta protein production | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20100069373-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BACE1, APP, BACE2 | GABRP 274/4885GABRD 648/4885GABRA1 999/4885 |
| US-20100056501-A1 | SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, APH1A | GABRP 198/4885GABRD 459/4885GABRA1 920/4885 |
| US-20050234039-A1 | Prevent forming deposits of amyloid protein on nervous systems; Alzheimer's disease; Down syndrome | APP, BACE1, PSEN1 | GABRP 527/4885GABRD 1054/4885GABRA1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.